Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer Explores ‘Dark Antigens’ With Enara In Potential $1bn Deal

Covers Novel Cancer Immunotherapy Targets And Therapies

Executive Summary

Announcing its first big pharma deal, the Oxford-based biotech says there could be more to come – with mRNA pioneers also interested in shining a light on hidden drug targets.

You may also be interested in...



Deal Watch: Sanofi Teams Up With Biond On Novel Checkpoint Inhibitor

Days after buying Kymab, Sanofi partners with Israel’s Biond on IO candidate targeting ILT2. Gilead again tackles functional cure of hepatitis B in alliance with Vir.

Denmark's IO Vaccine Biotech Attracts Investor Interest

Copenhagen-based start-up IO Biotech has raised a hefty €127m from a group of VC investors to accelerate its IDO- and PD-L1 targeted immuno-oncology approaches to the treatment of cancer.

AstraZeneca Sees Off Shareholder Revolt Over CEO’s Potential $25m Pay

A few years ago Pascal Soriot claimed to be the sector’s worst paid CEO, but share price-linked bonuses have bumped up his remuneration, and shareholders have now approved a new plan.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143613

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel